| MACS® Separation of human stem and progenitor cells |
 |
|
Stem cells have the potential to revolutionize tissue regeneration therapies. Therefore, crucial research is underway to identify basic mechanisms of stem cell biology as well as their potential to regenerate or engineer specific tissues or organs. Reproducibility of data and standardization of protocols is key to the unraveling the full potential of stem cells, in addition to the use of defined stem cell populations from the outset.
To support research into harnessing their extraordinary potential for future applications, Miltenyi Biotec offers high quality tools for the immunomagnetic isolation, phenotypic analysis, cultivation and molecular analysis of
- Pluripotent stem cells from many tissue sources:
can be isolated by their expression of CD133, a surface marker also described to be expressed on hemangioblasts – the progenitor of hematopoietic stem cells and endothelial progenitor cells (EPCs)1. It is also expressed on EPCs themselves2,3, hematopoietic stem and progenitor cells4, marrow stromal cells (MSCs) from cord blood5 and also on tissue-specific stem and progenitor cells, such as neural6,7, renal8, corneal9 and prostatic stem cells10.
For more information see flyer CD133 - the pluripotent stem cell marker.
Miltenyi Biotec – your partner for effective stem cell research.
References
1 Loges, S. et al. (2004) Stem Cells Dev. 13:229-242 [4218]
2 Peichev, M. et al. (2000) Blood 95:952-958 [931]
3 Gehling, U. et al. (2000) Blood 95:3106-3112 [934]
4 Yin, A.H. et al. (1997) Blood 90:5002-5012 [383]
5 Tondreau, T. et al. (2005) Stem Cells 23:1105-1112
6 Uchida, N. et al. (2000) Proc. Natl. Acad. Sci. USA 97:14720-14725 [933]
7 Cummings, B.J. et al. (2005) Proc. Natl. Acad. Sci. USA 102:14069-14074
8 Bussolati, B. et al. (2005) Am. J. Pathol. 166:545-555
9 Thill, M. et al. (2004) Invest. Opthalmol. Vis. Sci. 45:3519 [7392]
10 Richardson, G. et al. (2004) J. Cell Sci. 117:3539-3545 [7531] |
|
|
|
